Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Oct 2025

Slomovitz Brian M, Danziger Natalie, Quintanilha Julia C F, Kelly Andrew D, Li Gerald, Podder Vivek, Lin Douglas I, Graf Ryon P, Elvin Julia A, Herzog Thomas J

Abstract excerpt

OBJECTIVE: We sought to validate the prognostic utility of comprehensive genomic profiling (CGP)-based molecular stratification for patients with endometrial carcinoma and to assess co-occurring biomarkers across subtypes. METHODS: This study included patients from a de-identified nationwide (US-based) endometrial cancer clinicogenomic database who underwent CGP testing as part of routine care. Molecular subtypes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Polymerase II

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Gene Expression Profiling

Share to Microsatellite Instability

Share to Poly-ADP-Ribose Binding Proteins

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 40896848
DOI: 10.1016/j.ijgc.2025.102107

Genes

POLE
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of comprehensive genomic profiling for prognostic and potential therapeutic molecular classification of endometrial cancer.PMID 40896848Read ↗

Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center.Semantic proximity Read ↗

Molecular testing for endometrial cancer: An SGO clinical practice statement.Semantic proximity Read ↗

Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.Semantic proximity Read ↗

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Semantic proximity Read ↗

Association of Molecular Classification with FIGO Stage and Survival Outcomes in Endometrial Cancer.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing for Molecular Classification in the Management of Endometrial Cancer: An Observational Cohort StudySemantic proximity Read ↗

Analysis of Differences in the Classification of Endometrial Cancer Patients in PolandSemantic proximity Read ↗

Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.Semantic proximity Read ↗

Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment.Semantic proximity Read ↗

Identification of molecular subtypes for endometrial carcinoma using a 46-gene next-generation sequencing panel: a retrospective study on a consecutive cohort.Semantic proximity Read ↗

Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Semantic proximity Read ↗

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.